Ahead of an official commercial launch this fall, Mazor Robotics Lts. recently debuted Mazor X, which they are terming, “a transformative guidance platform for spine surgeries.” The company is positioning this device as a major technological step forward, moving the field of robotic-based surgery into more all-encompassing support than exists currently.
In a press release, Mazor Robotics CEO Ori Hadomi explains, “Mazor X is the culmination of a multi-year development effort to proactively address our target market, surgeon and patient needs for today’s reimbursement environment, by applying multi-disciplinary principles to achieve a Surgical Assurance platform.”
Hadomi adds, “The Mazor X platform expands the field of spine surgery from trajectory guidance to assisting surgeons with a total patient treatment strategy.”
The Mazor X is built upon a set of coordinated processes, including pre-operative analytics intended to aid practitioners in creating a full treatment strategy for each patient. That is in addition to an increasingly familiar robotic surgical arm to directly assist in the actual surgery. The Mazor X is also equipped with real-time verification technology meant to give surgeons multiple avenues to make certain the procedure is being executed according to plan. At this point, some components of the platform are still awaiting final FDA clearance.
News of the Mazor X system was essentially concurrent to the announcement that the Minneapolis-based Medtronic is prepared to up their investment in Mazor Robotics to the tune of $20 million. That financial boost comes less than two months after Medtronic’s initial strategic partnerships with the Israeli company were forged and was largely triggered by the new equipment’s unveiling.
Mazor X is slated for its proper commercial launch at the annual meeting of the North American Spine Society, taking place in Boston this fall.